House of Lords Business
Show full summary

Baroness Randerson to ask Her Majesty's Government, 

further to the Written Answer by Lord O'Shaughnessy on 18 July (HL529), whether the figure of £200 million represents only the cost of medicines for the treatment of hepatitis C, or whether it includes the cost of associated ancillary treatments; whether the NHS procurement process for hepatitis C drug treatments has achieved any cost savings; and if so, what is the value of those savings.

  HL2469

Question HL2469: tabled on 24 October 2017 and due for answer by 7 November 2017

This type of business sits within the Questions & Statements category.

This question has been answered by the relevant Government Department.

Question text

Baroness Randerson to ask Her Majesty's Government, 

further to the Written Answer by Lord O'Shaughnessy on 18 July (HL529), whether the figure of £200 million represents only the cost of medicines for the treatment of hepatitis C, or whether it includes the cost of associated ancillary treatments; whether the NHS procurement process for hepatitis C drug treatments has achieved any cost savings; and if so, what is the value of those savings.

  HL2469
Legend for business item text
† Item that is new or altered.
[I] Indicates that the member concerned has a relevant registered interest.
* Item is an oral question.
Numbers starting HL are unique identifiers for written questions, Bills or papers.

Member's Registered Interests

There are no interests to show.

Main Member

Baroness Randerson
Liberal Democrat
Life peer